Q-omics provides the consensus-scored ACTR3 profile across patient tissues and cancer cell-line models. ACTR3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ACTR3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ACTR3 protein abundance shows 33,756 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where ACTR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTR3 survival associations across molecular data types. ACTR3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTR3 RNA expression–survival associations across cancer types. High ACTR3 expression shows unfavorable associations in ACC, MESO, KIRP, UVM, LIHC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ACTR3 RNA expression.
This table summarizes ACTR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACTR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTR3 shows higher tumor expression in HNSC, KIRC, LIHC, KIRP, STAD and LUSC. The HNSC box plot shows higher ACTR3 RNA expression in tumor versus normal tissue (log2 FC = +0.838, t-test p < 0.001).
This table shows molecular features associated with ACTR3 in patient tissues and cancer cell lines. In patient samples, ACTR3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
